Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017

information fournie par Boursorama •20/03/2017 à 17:35

Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017

-A clinical development plan already well underway:
oNew clinical immune checkpoint inhibitors (ICIs) combination collaborations signed with Bristol-Myers Squibb for TG4010 (lung cancer) and with Merck KGaA/Pfizer for TG4001 (head and neck cancer)
oFirst patients dosed in trials combining ICIs with TG4010 (lung cancer) and with Pexa-Vec (solid tumors)
-Very favorable change in finance:
oNet loss significantly reduced: ?25.2 million in 2016 compared to ?46.4 million in 2015
oCash and cash equivalents increased: ?56.2 million as of December 31, 2016, increasing financial visibility until the end of 2018
-Acceleration of the clinical development plan will generate a rich news flow over the next 12 months

Conference call scheduled today at 6:00 PM CET (in English)